Suppr超能文献

7例特发性眼眶肌炎患者的长期预后

Long-term Outcome in 7 Patients With Idiopathic Orbital Myositis.

作者信息

Matsuo Toshihiko

机构信息

Department of Ophthalmology, Okayama University Hospital and Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan.

出版信息

Jpn Clin Med. 2019 Aug 12;10:1179670719866525. doi: 10.1177/1179670719866525. eCollection 2019.

Abstract

PURPOSE

Idiopathic orbital myositis, a rare disease of unknown cause, presents a diagnostic puzzle because the diagnosis is based on the exclusion of other diseases. This study aims at elucidating its long-term outcome to answer a clinical question whether idiopathic orbital myositis would be a distinct clinical entity.

METHODS

Retrospective review was made on 7 consecutive patients (6 men and 1 woman) with the age at the initial visit ranging from 33 to 69 years (mean, 45.8 years) who were diagnosed with idiopathic orbital myositis and followed for 5 years or more (mean, 9.2 years) at a referral-based hospital.

RESULTS

Chief complaint at the initial visit was diplopia in 4 patients, blurred vision in 2 patients, and proptosis in 1 patient. On magnetic resonance imaging, 4 patients showed enlargement of a single extraocular muscle on unilateral side while 3 patients showed enlargement of multiple extraocular muscles on unilateral side or bilateral sides. No patient developed systemic diseases or other orbital lesions in the long-term follow-up. All patients at the last visit were free from symptoms, including diplopia, after tapering of prednisolone at the initial dose of 20 to 60 mg daily.

CONCLUSION

Idiopathic orbital myositis had a favorable long-term outcome with corticosteroid administration and appears to be a distinct clinical entity without systemic involvement.

摘要

目的

特发性眼眶肌炎是一种病因不明的罕见疾病,由于其诊断基于排除其他疾病,因此存在诊断难题。本研究旨在阐明其长期预后,以回答特发性眼眶肌炎是否为一种独特临床实体这一临床问题。

方法

对一家转诊医院连续7例(6例男性,1例女性)初诊年龄在33至69岁(平均45.8岁)、被诊断为特发性眼眶肌炎且随访5年或更长时间(平均9.2年)的患者进行回顾性研究。

结果

初诊时的主要症状为,4例患者出现复视,2例患者视力模糊,1例患者眼球突出。在磁共振成像检查中,4例患者表现为单侧单条眼外肌增粗,3例患者表现为单侧或双侧多条眼外肌增粗。在长期随访中,无患者出现全身性疾病或其他眼眶病变。在初始剂量为每日20至60毫克的泼尼松龙逐渐减量后,所有患者在最后一次就诊时均无包括复视在内的症状。

结论

特发性眼眶肌炎经皮质类固醇治疗后长期预后良好,似乎是一种无全身累及的独特临床实体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f75/9109134/d1afe8857f9f/10.1177_1179670719866525-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验